Kestra Medical (KMTS) Director Ladone Sells Shares, Receives RSUs

What Happened

• Ladone Mary Kay (Director) reported two transactions: a nondiscretionary open‑market sale of 3,908 common shares on 2026-09-08 for a weighted average price of $25.20 (total ≈ $98,464), and an award/acquisition of 7,217 restricted stock units (RSUs) on 2026-09-09. The sale was a sell‑to‑cover to satisfy tax withholding related to RSU vesting/settlement; the RSUs each represent one common share and will vest on September 9, 2027, subject to continued service.

Key Details

• Transaction dates and prices:
  • Sale: 2026-09-08 — 3,908 shares sold; weighted average price $25.20; reported price range $24.91–$25.43.
  • Award: 2026-09-09 — 7,217 RSUs granted (no per‑share price reported for awards).
• Value: Sale proceeds ≈ $98,464; award value not shown (typical RSU grants reported as share counts).
• Shares owned after transaction: Not explicitly summarized in this Form 4; filing notes include 17,512 common shares received from West Affum Holdings, L.P. in a pro rata distribution (exempt under Rule 16a‑9).
• Notable footnotes: F1 — sale was a nondiscretionary sell‑to‑cover for tax withholding; F2 — sale price is weighted average with a disclosed range; F4 — RSUs vest 9/9/2027, subject to continued service.
• Filing timeliness: Form 4 was filed on 2026-09-10 for transactions on 9/8 and 9/9, which is within the usual two-business-day reporting window.

Context

• The sale was a routine sell‑to‑cover for tax withholding tied to equity compensation and should not be read as an independent bearish signal. The award (7,217 RSUs) is an acquisition of future shares that vests over time; such grants are compensation-related and often reflect retention/compensation rather than open‑market buying.